Overcoming the
GI Barrier.
Peptides are fragile chains of amino acids. When administered orally, they face immediate destruction from gastric acid (pH ~1.5) and proteolytic enzymes in the upper gastrointestinal tract.
Historically, achieving systemic availability meant using subcutaneous injections. Oral supplements typically yield less than 1% bioavailability—rendering the payload biologically useless.
The Bioavailability Chasm
Gastric degradation limits standard oral peptide efficacy to <1%.
Mechanism of Delivery
VERISORB™ subverts the gastrointestinal tract using a three-phase matrix.
Liposomal Encapsulation
The peptide active pharmaceutical ingredient (API) is localized within a nanoscale lipid bilayer vesicle, protecting the fragile amino acid bonds from enzymatic breakdown.
Cold Desiccation
Liquid liposomes normally require refrigeration. Our freeze-drying process converts the liposomes into a room-temperature stable, highly porous tablet that retains the intact matrix.
Mucosal Transfer
Upon sublingual contact, the tablet rapidly hydrates. The highly vascularized mucosal tissue under the tongue allows the liposomes to permeate directly into systemic circulation.
The Cmax Differential
Preclinical models testing early iterations of the matrix technology demonstrated a multi-fold pharmacokinetic advantage. In validated laboratory studies observing Ivermectin delivery, the underlying liposomal matrix yielded a markedly higher maximum serum concentration (Cmax) than the unmodified compound.*
Standard vs. Sublingual vs. Injection
Sublingual lipid nanoparticle (LNP) matrices typically suffer from rapid degradation at room temperature. VERISORB™ utilizes a proprietary cold-desiccation process that stabilizes the lipid bilayer.
* In preclinical animal research models, formulations utilizing the core lipid-matrix technology of VERISORB™ demonstrated a multi-fold increase in peak bloodstream absorption (Cmax) and substantially higher Area Under Curve (AUC) versus standard unformulated oral delivery. Clinical outcomes in humans may vary depending on strict adherence to sublingual application timing.